SCHEMBL4143300

SCHEMBL4143300

Nc1nc(Cc2cc(F)cc(F)c2)cc(=O)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.53
CYP3A4 P08684 1/20 0.46
BLM P54132 1/20 0.46
XDH P47989 4/20 0.41
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.37
ABL1 P00519 1/20 0.37
RIN1 Q13671 1/20 0.37
CDC7 O00311 1/20 0.36
ROCK2 O75116 1/20 0.36
MAP4K4 O95819 1/20 0.36
PIM1 P11309 1/20 0.36
PRKACA P17612 1/20 0.36
CDK2 P24941 1/20 0.36
GSK3B P49841 1/20 0.36
HIPK2 Q9H2X6 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
TYMS P04818 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5907152 0.79 BACE1 (0.74) BACE1CYP3A4BLMXDHPOLB
SCHEMBL13914840 0.76 BACE1 (0.57) BACE1CYP3A4BLMXDHPOLB
SCHEMBL10617521 0.75 BACE1 (0.62) BACE1CYP3A4BLMXDHPOLB
SCHEMBL4499203 0.73 BACE1 (0.48) BACE1CYP3A4BLMXDHPOLB
SCHEMBL4150133 0.73 BACE1 (0.57) BACE1CYP3A4BLMXDHPOLB
SCHEMBL6068586 0.73 POLB (0.55) BACE1CYP3A4BLMXDHPOLB
SCHEMBL2403638 0.72 BACE1 (0.73) BACE1CYP3A4BLMXDHPOLB
SCHEMBL4809195 0.69 BACE1 (1.00) BACE1CYP3A4BLMXDHPOLB
Benzene SCHEMBL8508944 0.69 BACE1 (0.69) BACE1CYP3A4BLMXDHPOLB
SCHEMBL1204537 0.68 BACE1 (0.57) BACE1CYP3A4BLMXDHPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221579-A1 Substituted Amino-Compounds and Uses Thereof ASTEX THERAPEUTICS (GB) 2009-09-03 US disclosed
US-20090062282-A1 Substituted Amino-Pyrimidones and Uses Thereof ASTRAZENECA AB (SE) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221579-A1 Substituted Amino-Compounds and Uses Thereof APP, PSEN1, BACE1 BACE1 3/4885CYP3A4 2100/4885BLM 3274/4885
US-20090062282-A1 Substituted Amino-Pyrimidones and Uses Thereof APP, PSEN1, PSEN2 BACE1 4/4885CYP3A4 1569/4885BLM 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.